



EPIAXIS THERAPEUTICS

ExpiAxis Company Profile

Overview

EpiAxis Therapeutics is a Canberra based immuno-oncology (IO) company, which is pursuing a discovery and translational program directed at the prevention of metastatic disease. The program is focused on the pivotal epigenetic enzymes controlling the proliferation of circulating tumour cells (**CTC**) and cancer stem cells (**CSC**). These cells are considered responsible for the initiation and maintenance of metastatic disease. These enzyme targets are the nuclear bound lysine-specific demethylase 1 (**LSD1**) and its upstream regulator, the theta isoform of protein kinase C (**PKC θ**).

The Company's proprietary "first in class" non-catalytic epigenetic inhibitors elicit a compelling IO response. This includes the abatement of the CTC and CSC burden; augmentation of immune checkpoint blockage; sensitisation of the immune response within the tumour microenvironment; as well as primary tumour abatement.

The research identifying these targets, and the intellectual property (**IP**) that resulted from it, was developed by Professor Sudha Rao and colleagues at the University of Canberra (**UC**), Australia. The Company is focused initially on the prevention of metastatic breast cancer, with other CTC/CSC mediated diseases such as ovarian, pancreatic, colon, melanoma, lung and liver cancers to be pursued later.

The Company has commenced a Phase 1b program, using an "off label" drug that also targets LSD1 in metastatic breast cancer as a "proof of concept" study. In parallel, the Company is advancing its proprietary epigenetic inhibitors, as "druggable candidates" for preclinical development.

EpiAxis Therapeutics is positioning itself to become the leading cancer recurrence prevention company with its proprietary epigenetic inhibitors included in the standard of care (**SoC**) with chemotherapy.

For further information, please visit: epiaxistherapeutics.com

Speaker Profile

Dr Jeremy Chrisp, Founding Chief Executive Officer and Director



Dr Jeremy Chrisp is a biotechnology entrepreneur with extensive experience in the commercialisation of Australian technology. His focus is on business development and the management of early stage opportunities. Jeremy holds a PhD in physiology from the University of Canterbury (NZ) and is a Fellow of the Australian Institute of Company Directors (AICD).

He has over twenty-nine years' experience in the Australian healthcare market, having worked with leading global multinational companies, including Merck & Co, Stryker, Becton Dickinson & Medtronic.